<DOC>
	<DOCNO>NCT02607735</DOCNO>
	<brief_summary>This study evaluate safety efficacy treatment sofosbuvir/velpatasvir/voxilaprevir ( SOF/VEL/VOX ) adults chronic HCV infection previously receive treatment direct-acting antiviral therapy . Subjects randomize placebo may eligible deferred treatment active SOF/VEL/VOX .</brief_summary>
	<brief_title>Safety Efficacy Sofosbuvir/Velpatasvir/Voxilaprevir Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Key Willing able provide write informed consent HCV RNA ≥ 10^4 IU/mL screen Chronic HCV infection ( ≥ 6 month ) Treatment experience direct act antiviral medication HCV Use protocol specify method contraception Key Current prior history clinically significant illness may interfere participation study Screening ECG clinically significant abnormality Laboratory result outside acceptable range screen Pregnant nursing female Chronic liver disease cause HCV Infection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV ) Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Chronic Hepatitis C Infection</keyword>
</DOC>